DIA

INDIA ANNUAL MEETING

Where India Meets the World in Healthcare Innovation.
Global Impact, Locally Delivered.

NOVEMBER 18-19, 2026
CIDCO Auditorium & Convention Centre, Navi Mumbai, India

OVERVIEW

DIA India Annual Meeting (IAM) - 2026 marks a defining moment for India's life sciences and healthcare ecosystem. As science, technology, and regulation converge at unprecedented speed, IAM 2026 serves as a platform where future-ready strategies are shaped, tested, and translated into real-world impact.

Anchored in the theme "Where India Meets the World in Healthcare Innovation," the meeting brings together global perspectives and local expertise to drive meaningful, scalable impact.

Bringing together leaders from pharma, biotech, medtech, regulators, academia, and technology, the meeting goes beyond dialogue, enabling decision-making, collaboration, and execution across the full product lifecycle.
With six focused tracks and two flagship plenaries, IAM 2026 is designed for those not just adapting to change, but shaping what comes next.

WHAT TO EXPECT

Learning Objectives

- Gain forward-looking insights into emerging therapies, technologies, and regulatory models
- Understand how to design agile, patient-centric development strategies in a rapidly evolving environment
- Explore practical approaches to AI, real-world evidence, and digital transformation
- Engage directly with regulators and industry leaders to align on expectations and best practices
- Build cross-functional and cross-sector collaborations that accelerate innovation
- Take home actionable frameworks to improve decision-making, compliance, and impact

Who Should Attend

- *Pharma, Biotech & MedTech Leaders:*
  R&D, Clinical Development, Regulatory Affairs, Quality, Safety, Medical Affairs, Market Access
- *Regulatory Authorities & Policy Leaders:*
  India and global agencies, regulatory strategists, compliance leaders
- *Clinical & Research Professionals:*
  Investigators, trial managers, biostatisticians, medical writers
- *Technology & Data Leaders:*
  AI, digital health, analytics, RWE, IT and platform providers
- *CROs & Solution Providers:*
  Clinical, regulatory, PV, data, and digital services
- *Academia & Research Institutions*
- *Students & Young Professionals:*
  The next generation of life sciences leaders
- *Industry Associations & Policy Influencers*

DIA India Pvt. Ltd. Cowork30, Office #201, ACME Plaza-2, Chakala, Andheri Kurla Road, Andheri (East) Mumbai – 400059
For more information, please write to us at india.meetings@diaglobal.org

STEERING COMMITTEE

C. Palani Palaniappan
Chair, DIA Global Board. CEO, Aridica Corporation, USA

Chitra Lele
Managing Director, Life Sciences Consulting, NTT DATA, India

Vivek Ahuja
EVP - Global Delivery Excellence, Strategy & Growth - PV, EVERSANA

Sridevi Nagarajan
DIA AI Consortium Co-Chair, Founder & Director, AyusArogya Ltd. UK

Sanish Davis
Senior Medical Director, Clinical Science-Oncology, Takeda, India

Gaurav Mathur
Senior Director, Regulatory Affairs, Parexel International, India

Subrat Ray
Director Global Medical Strategy, Organon, India

Praveen Raj
Head of Global Medical Affairs, Biocon Biologics, India

Ashok Kumar Swain
General Manager & Executive Director DIA (India)

PROGRAM COMMITTEE

Srirupa Das
Vice President, Medical and Regulatory Affairs, Zydus Healthcare

Shweta Pradhan
Head R&D Operations India, IQVIA

Manjusha Rajarshi
Founder - Regulus Healthcare. Partner at Roots-Simplified Research & Consulting LLP

Anirban Roy Chowdhury
AVP & Head - Development Center of Excellence Specialty Medicine, Sun Pharma

J Vijay Venkatraman
Managing Director and CEO, Oviya Medsafe Pvt Ltd

Senthilnathan M
Country Head – Medical Affairs Cipla Ltd

Meenakshi Mudiraj
Senior Director Global Regulatory Affairs Teva Pharmaceuticals

Mukesh Kumar
Chief Scientific Officer CLINEXEL

Sushant Kumar
Head – R&D Immunoadoptive Cell Therapy Pvt. Ltd. (ImmunoACT)

Samuel Solomon
Vice President Regulatory Affairs Intas Pharmaceuticals

Prantika Khetarpal
Pharmacovigilance Industry Leader and Council Director, TCS

Prachet Mohanty
Associate Director, Research & Development IT, BMS GCC

PROGRAM AGENDA

AGENDA: Day 1, 18 November 2026; Wednesday			
8:00 - 8:45AM	**Registration and Welcome Coffee**		
8:45 - 9:00AM	**Welcome Remarks from DIA**		
9:00 - 11:00AM	**Opening Plenary Session** **Theme: India 2047 (Viksit Bharat) – From the Pharmacy of the World to the Innovation Engine of the World**		
9:00-9:10AM	**CDSCO Opening Address**		
9:10-9:20AM	**US FDA Opening Address**		
9:20-9:40AM	**Keynote: India 2036 – From Global Supplier to Global Healthcare and Innovation Powerhouse**		
9:40-10:00AM	**Keynote: India and the GLP-1 Revolution: Can the Diabetes Capital Lead on Access, Affordability and Innovation**		
10:00 - 11:00AM	**Plenary Panel Discussion: The Billion-Dollar Question – What Will It Take for India to Produce the Next Global Biopharma Giant?** Moderator**: Vivek Ahuja,** EVP - Global Delivery Excellence, Strategy & Growth - PV, EVERSANA Panelists:		
	Tea Break		
11:30-5:30 PM	**Track 1: Regulatory Science & Policy (RS)**	**Track 2: Advanced Therapy Medicinal Products (AT)**	**Track 3: Clinical Development (CD)**
	Track Theme: Architecting Smarter Regulatory Pathways to Accelerate Access to Life-Changing Therapies.	*Track Theme: Advanced Therapies: From Innovation to Patient Outcomes*	*Track Theme: Advancing clinical development through collaboration, evidence, and innovation.*
11:30 - 1:00PM	**RS.S1: Future-Ready Regulatory Frameworks: Adapting to Global Change** Session Chair: **Samuel Raj Solomon,** Vice President Regulatory Affairs Intas Pharmaceutical	**AT.S1: Next-Generation Advanced Therapies shaping health care** Session Chair: **Praveen Raj,** Head of Global Medical Affairs, Biocon Biologics	**CD.S1: India as a Biopharma Hub for Global Clinical Development** Session Chair: **Shweta Pradhan,** Head R&D Operations India, IQVIA
	RS.S1.T1: Are You Ready for the Changes to the U.S. National Drug Code and Barcode Requirements? **Leyla Rahjou,** Esfandiary, CDER, U.S. FDA	**AT.S1.T1: Rewriting the Cancer Playbook: The Promise of Advanced Therapies in Oncology**	**CD.S1.T1: Strategic Vision: India as a Global Biopharma Hub by 2030** **Sannie Chong**, Senior Director, AP Regulatory Policy at MSD
	RS. S1.T2: Navigating the EU MDR Transition Extension: Regulatory Strategy, Risk-Based Planning, and Compliance Execution **Dr Vivek Singh Bhagoor,** Manager, Syneos Health	**AT.S1.T2: Radiopharmaceuticals: The Next Frontier in Precision Oncology?**	**CD.S1.T2: India's Clinical Trial Advantage: What Will It Take to Compete Globally?**

PROGRAM AGENDA

AGENDA: Day 1, 18 November 2026; Wednesday			
	RS.S1.T3: What Next in Global Public Standards to Foster Biologics Development? **Allison Radwick,** Senior Regulatory and Policy Communications Manager, US Pharmacopeia	**AT.S1.T3: Panel Discussion: From Innovation to Impact: Can India Build a Global Ecosystem for Advanced Therapies?** Moderator: **Praveen Raj**	**CD.S1.T3: Panel Discussion: Is India Ready to Become a Preferred Destination for Global Clinical Trials?** Moderator: **Shweta Pradhan**
	RS.S1.T4: Panel Discussion: What does a truly future-ready regulatory framework look like? Moderator: **Samuel Raj Solomon**		
	Lunch Break		
2:00 - 3:30PM	**RS.S2: Digital Transformation and AI in Regulatory Science** Sesion Chair: **Gaurav Mathur,** Senior Director, Regulatory Affairs, Parexel	**AT.S2: Advancing Cell & Gene Therapies** Sesion Chair: **Sushant Kumar,** Head – R&D, Immunoadoptive Cell Therapy Pvt. Ltd. (ImmunoACT)	**CD.S2: Bridging the Execution Gap in Global Clinical Development Programs** Session Chair: **Anirban Roy Chowdhury,** AVP & Head - Development Center of Excellence Specialty Medicine, Sun Pharma
	RS.S2.T1: AI in Regulatory Decision-Making: Hype, Reality, and the Path Forward **Swapna Teja Gundala**, Manager, Regulatory Affairs, Parexel	**AT.S2.T1: CMC Strategies for Cell and Gene Therapy in India: Starting Materials, Comparability and Quality Control** **Annu Uppal**, Director Scientific Affairs, US Pharmacopeia	**CD.S2.T1: Risk-Based Quality Management: Turning Clinical Trial Risk into Action**
	RS.S2.T2: Advancing Regulatory Convergence through Digital, Collaboration Enabled Post Approval Submissions **Ganesh Pawbake,** Senior Manager Regulatory Affairs, Amgen Technology Private Limited	**AT.S2.T2: Cell & Gene Therapy: Are Regulatory Pathways Keeping Pace with Science?**	**CD.S2.T2: Beyond the Clinical Trial: Can Real-World Evidence Transform Clinical Development?**
	RS.S2.T3: Operationalizing Clinical Protocols through ICH M11 CeSHarP from a Medical Writing Perspective **Mahvash Iram,** Manager-Medical Writing, Teva Pharmaceuticals	**AT.S2.T3: Panel Discussion: Cell & Gene Therapy at Scale: What Will It Take to Move from Breakthrough to Routine Care?** Moderator**: Sushant Kumar**	**CD.S2.T3: Panel Discussion: Why Do Global Clinical Trials Still Fail at Execution? Bridging the Gap Between Strategy and Reality** Moderator: **Anirban Roy Chowdhury**

PROGRAM AGENDA

AGENDA: Day 1, 18 November 2026; Wednesday

	RS.S2.T4: Panel Discussion: Real-World Applications: How Organizations are Adopting AI in Regulatory Workflows? Moderator: **Gaurav Mathur**		
	Tea Break		
4:00 - 5:30PM	**RS.S3: Advancing Global Collaboration and Operational Excellence** Session Chair**: Meenakshi Mudiraj,** Senior Director Global Regulatory Affairs Teva Pharmaceuticals	**AT.S3: Expanding Patient Access to Advanced Therapies & Technologies** Sesion Chair: **Manjusha Rajarshi,** Founder Regulus Healthcare Partner at roots-simplified Research and Consulting LLP	**CD.S3: How Technologies help improve Clinical Development** Sesion Chair: **Mukesh Kumar,** Chief Scientific Officer, CLINEXEL
	RS.S3.T1: Seeing Risk Before It Becomes Failure: Leveraging Early Risk Intelligence in GMP Systems **Dipankar Kaul**, Director, Kauledge	**AT.S3.T1: Advanced Therapies, Complex Barriers: What Stands Between Innovation and the Patient?**	**CD.S3.T1: From Support to Autonomy: Navigating the Dual Frontier of AI as Enabler and AI as Agent in Clinical Development** **Jasmin Johnson**, VP – Strategy, Veeva Systems
	RS.S3.T2: Advancing International Collaborative Regulatory Assessments to Accelerate Patient Access **Irene Chan**, Executive Director, Global Policy and Strategy - Asia Pacific, Eli Lilly and Company	**AT.S3.T2: Bench to Bedside: What Does It Really Take to Deliver Advanced Therapies?**	**CD.S3.T2: Can Digital Biomarkers Make Clinical Trials Smarter, Faster and More Patient-Centric?**
	RS.S3.T3: Driving Operational Excellence: Enhancing Data Quality and governance through Master-Reference Data Harmonization **Sailasri Yeleswarapu**, RA structured Data Submission Manager, Novartis Healthcare Pvt Ltd	**AT.S3.T3: Panel Discussion: From Innovation to Access: Can India Deliver Advanced Therapies at Scale?** Moderator: **Manjusha Rajarshi**	**CD.S3.T3: Panel Discussion: AI as Clinical Development Partner: How Far Should We Trust the Machine?** Moderator: **Mukesh Kumar**
	RS.S3.T4: Panel Discussion: From Regulatory Silos to Global Collaboration: Can Convergence Accelerate Patient Access Moderator: **Meenakshi Mudiraj**		

Day 1 Ends: Wrap Up

PROGRAM AGENDA

AGENDA: Day 2, 19 November 2026; Thursday			
8:45 - 9:00AM	**DIA Welcome Remarks Day 2**		
9:00 - 9:30AM	**Plenary Keynotes**		
9:00 - 9:15AM	**KNA 4: Human Led AI at Global Scale: Speed, Quality, and Trust in Clinical Development** **Sanjay Vyas**, President, Safety & Logistics and Country Head of India, PAREXEL		
9:15 - 9:30AM	**KNA 5: Beyond Patient Recruitment: Building a Future-Ready Clinical Research Ecosystem in India**		
9.30 - 3.30AM	**Track 4: Pharmacovigilance (PV)**	**Track 5: Medical Affairs (MA)**	**Track 6 – Data Science & Artificial Intelligence (DS)**
	Track Theme: The Great Reinvention of Pharmacovigilance	*Track Theme: From insights to Evidence to impact: Transforming Medical Affairs for Better Health Outcomes*	*Track Theme: Harnessing the power of data and artificial intelligence for Smarter healthcare decision.*
9:30 - 11:00AM	**PV.S1: Will AI Replace the PV Professional or Reinvent the Role?** Session Chair**: Vivek Ahuja,** EVP - Global Delivery Excellence, Strategy & Growth - PV, EVERSANA	**MA.S1: The Strategic Role of Medical Affairs in Shaping Healthcare Value** Session Chair**: Srirupa Das,** Vice President, Medical and Regulatory Affairs, Zydus Healthcare	**DS.S1: Making AI Work in the Real World: From Promise to Impact** Session Chair**: Chitra Lele,** Managing Director, Life Sciences Consulting, NTT DATA
	PV.S1.T1: AI has arrived for PV, are we ready with the Governance? **Abhishek Kumar**, VP, Eliquent Life Sciences	**MA.S1.T1: Medical Affairs–Led Lifecycle Evidence Orchestration to Strengthen Decision** **Neha Neharika,** Senior Medical Writer, Syneos Health	**DS.S1.T1: Why AI Fails in Real-World Healthcare Deployment: An Exploratory Stakeholder Survey and Implementation-Informed Framework** **Manthan Nikesh Mehta,** AGM-Medical Affairs, Alkem Laboratories Ltd
	PV.S1.T2: Next Gen PV- Where AI Meets the Patient Voice: Turning Patient Voices into Safety Intelligence **Renu Sharma,** Senior Director, Patient Safety Operations, PAREXEL	**MA.S1.T2: Breaking Silos: How Cross - Functional Collaboration Amplifies Medical Affairs Impact Across the Healthcare Ecosystem**	**DS.S1.T2: Designing Scalable Digital Access in Medical Information: A Phased WhatsApp Customer- Engagement Model in India** **Namrata Clement Saldanha,** Senior Medical Information Officer, Pfizer Limited
	PV.S1.T3: Panel Discussion: From Digital Health to Digital Safety: Building India's Next-Generation Pharmacovigilance Ecosystem Moderator: **Vivek Ahuja**	**MA.S1.T3: Panel Discussion: From insight to Impact: Navigating Lifecycle Challenges and Leveraging Cross-Functional Partnerships, how MA becomes strategic driver in decision making and leveraging CFT** Moderator: **Srirupa Das**	**DS.S1.T3: Panel Discussion: How do we make AI work in the Real World? From Algorithms to Adoption, Trust and Impact** Moderator: **Chitra Lele**
	Tea Break		

PROGRAM AGENDA

AGENDA: Day 2, 19 November 2026; Thursday			
11:30-1:00 PM	**PV.S2: Reinventing Signal Management: From Reactive Surveillance to Predictive Safety Intelligence** Session Chair**: J Vijay Venkatraman,** Managing Director and CEO, Oviya Medsafe Pvt Ltd	**MA.S2: Building Evidence with Real World for Health Outcomes** Session Chair: **Senthilnathan M,** Country Head – Medical Affairs Cipla Ltd	**DS.S2: Getting the Data Foundation Right: Enabling AI and Advanced Analytics** Session Chair**: Prachet Mohanty,** Associate Director, Research & Development IT, BMS GCC
	PV.S2.T1: Integrated Safety Systems Across the Product Lifecycle **Isha Shukla,** Associate Director Quality, Primevigilance	**MA.S2.T1: From Data to Decision: Does Real-World Evidence Changes Practice in India?** **Manthan Nikesh Mehta,** AGM-Medical Affairs, Alkem Laboratories Ltd	**DS.S2.T1: Enabling Advanced Analytics and Data Interoperability Through Standards-First Clinical Data Management** **Sumeela Nair,** Director, Parexel
	PV.S2.T2: EudraVigilance Monitoring & Signal Management: Navigating Changes Introduced by EU 2025/1466 **Krathika Bhat,** Pharmacovigilance and Medical Sciences Manager, Dr. Ebeling & Associates	**MA.S2.T2: Role of HEOR and HTA in Healthcare Decision-Making** **Gnana Prathyusha Barla,** Analyst 2 Business Process Transactions Regulatory Publishing, DXC TECHNOLOGIES	**DS.S2.T2: Protocol-Driven Synthetic SDTM Generation for AI-Enabled Clinical Development and Regulatory Data Transformation** **Hanuragav Muthiah Giri**, Data Scientist, Care2data
	PV.S2.T3: Panel Discussion: Can We Predict the Next Safety Signal Before Patients Are Harmed? Moderator: **J Vijay Venkatraman**	**MA.S2.T3: Panel Discussion: Navigating Challenges in RWE Generation in India** Moderator: **Senthilnathan M**	**DS.S2.T3: Panel Discussion: Can AI Deliver Without Interoperable Data? Breaking the Silos That Hold Life Sciences Back** Moderator**: Prachet Mohanty**
	Lunch Break		
2:00 - 3:30PM	**PV.S3: Future-Ready Pharmacovigilance: Geographies, Advanced Therapies, and Emerging Risks** Session Chair: **Prantika Khetarpal,** Pharmacovigilance Industry Leader and Council Director, TCS	**MA.S3: Driving Impact: India and Beyond** Session Chair**: Subrat Ray,** Director Global Medical Strategy, Organon	**DS.S3: How Far Can AI Transform Drug Development?** Session Chair: **Sridevi Nagarajan,** DIA AI Consortium Co-Chair, Founder & Director, AyusArogya Ltd. UK
	PV.S3.T1: Comparative Safety Profile of Lutetium-177 Radioligand Therapies **Vidisha Vivek Parulekar,** Senior Drug Safety Physician, Parexel	**MA.S3.T1: Global Capability Centers (GCC) as Strategic Innovation Hubs: Is India Ready to Lead Beyond Border**	**DS.S3.T1: Precision Design: Leveraging AI and Predictive Analytics to Optimize Global Clinical Trials** **Shailesh Bajpai,** Solution Consultant, MEDIDATA

PROGRAM AGENDA

AGENDA: Day 2, 19 November 2026; Thursday			
2:00 - 3:30PM	**PV.S3.T2: Strengthening Pharmacovigilance in SAARC LMICs – Lessons from Africa and India** **Kaveesha Fernando,** PhD Candidate, Duksung Women's University	**MA.S3.T2: Shaping Clinical Practice: Influencing Guidelines, Decision Makers, and Therapy Adoption**	**DS.S3.T2: AI-Enabled Quality Assurance in Medical Writing Using Agent- and Prompt-Based AI Solutions** **Smitha Sreedharan,** Associate Director, Medical Writing, IQVIA
	PV.S3.T3: Panel Discussion: Next-Generation Drug Safety: Managing Risks in a Rapidly Changing Therapeutic Landscape Moderator: **Prantika Khetarpal**	**MA.S3.T3: Publication that Drive Change: Through high impact Medical evidence**	**DS.S3.T3: AI in Drug Development: Balancing Automation, Autonomy and Accountability** Moderator: **Sridevi Nagarajan**
		MA.S3.T4: Panel Discussion: Can India shape the future of Health care. Moderator: **Subrat Ray**	
TEA BREAK			
4:00 - 5:00PM	**Closing Plenary Session**		
4:00 - 4:15PM	**Keynote: From Molecule to Medicine: How AI Is Redefining the Drug Development Continuum**		
4:15 - 5:00PM	**Panel Discussion: The Future of Medicines: Who Will Shape the Next Era of Healthcare?**		
5:00 - 5:15PM	**Vote of Thanks** **Ashok Kumar Swain,** General Manager & Executive Director, DIA (India)		
Day 2 Ends: Wrap Up			

OUR SPONSORS & PARTNERS

PAYMENT INFORMATION

Meeting registration for an individual participant with ONLINE payment can be completed directly through the DIA website meeting Registration page.

For group registrations, please contact the meeting manager (below table).

BANK ACCOUNT details for other modes of payment:
Account Name: DIA (INDIA) PRIVATE LIMITED
Account No: 061010200024611
Bank Name: AXIS BANK LIMITED
Branch Name: Dhiraj Baug, Near Hari Niwas Circle,
LBS Marg, Thane (W) – 400602
IFSC Code: UTIB0000061 MICR Code: 400211013
Swift Code: AXISINBB061

Add Membership for Instant Discounts

Join DIA today to enjoy discounted meeting registration fees and unlock all membership benefits. Visit https://www.diaglobal.org and select the "Membership" option under the "Get Involved" tab for more details.

Select the 'Add Membership' option during registration to instantly avail membership discount on the registrations fee.

CHEQUE / DRAFT

Completed form, along with draft/cheque made payable to DIA (India) Private Limited should be sent to:
Vinita Shetty | Finance Manager
DIA (India) Pvt. Ltd.
Cowork30, Office #201, ACME Plaza-2, Chakala
Andheri- Kurla Road, Andheri (East), Mumbai – 400059
Email: vinita.shetty@diaglobal.org Cell: +91 9769764645

PRIVACY POLICY

DIA respects the privacy of all its members and customers. To view our policy, click the link below: https://www.diaglobal.org/en/about-us/privacy-policy. You agree that your personal data will be transferred to DIA in the US.

*Academia Category

The ACADEMIA category applies to individuals with primary, full-time affiliation to a bona fide academic institution, and includes STUDENTS. Proof of appointment or enrollment is required.

REGSITRATION FEES

Category	Early Bird Rate (till 31 Aug 2026)	Advance Rate (1 Sep – 30 Sep 2026)	Standard Rate (from 1 Oct Onwards)
Industry – Non-member	INR 13,000 +GST	INR 15,000 +GST	INR 18,000 +GST
Industry – Member	INR 10,000 +GST	INR 12,000 +GST	INR 15,000 +GST
Academia*/ Non-Profit / Govt – Member	INR 7,000 +GST		
Academia*/ Non-Profit / Govt – Non-member	INR 9,000 +GST		

For Group Registrations: Please contact Gauraja Deshpande | Mob: +91 8082560804 | Gauraja.Deshpande@diaglobal.org

DIA Cancellation & Refund Policy:

1. **Cancellation Deadline:** Cancellations must be submitted in writing and received by 18th October 2026 to qualify for a refund. Cancellations received after this date will not be eligible for any refund.
2. **No-Shows and Late Cancellations:** Registrants who do not cancel in writing by the deadline and do not attend the event will remain liable for the full registration fee. No refunds will be issued under such circumstances.
3. **Administrative Fee:** A 25% administrative fee will be deducted from all eligible refunds.
4. **Force Majeure:** DIA reserves the right to alter the venue or the date. In the event of cancellation or postponement due to circumstances beyond DIA's control (including but not limited to natural disasters, public health emergencies, government restrictions, or strikes), DIA shall not be held liable for any resulting costs or damages, and refunds may be partially or fully waived at DIA's discretion.
5. **Travel and Accommodation Liability:** DIA is not responsible for any airfare, hotel, or travel-related expenses incurred by participants. These arrangements are the sole responsibility of the registrant.
6. **Refund Processing and Currency Disclaimer:** Eligible refunds will be processed within 60 business days after the conclusion of the event. Refunds will be made in the original transaction currency, and DIA will not be liable for any bank charges or currency fluctuations.

DIA REGISTRATION FORM

Date: (DD/Month/2026)

Please check the applicable category: ☐ Industry ☐ Government ☐ Academia ☐ Student

Last Name | **First Name** | **Middle Initial** | **Please check one:** ☐ Mr. ☐ Ms. ☐ Dr. ☐ Prof.

Job Position | **Name of Organization** (Primary Affiliation)

Address (As per your country's format) | City | Postal Code | Country | ☐ Home ☐ Business

Mobile Number (Required) | **Telephone Number**

Email (Required for confirmation)

If sending this form by post or courier, please provide a copy of the registrant's business card.